DEFA14A: Biotricity Inc. Seeks Shareholder Approval for Director Elections, Auditor Ratification, and Equity Issuance at Upcoming Annual Meeting

Biotricity Inc. is soliciting proxies for its annual shareholder meeting on August 15, 2024, covering director elections, auditor ratification, and approval for a common stock issuance upon conversion of preferred stock.

Summary

• Biotricity Inc. is holding its annual shareholder meeting on August 15, 2024.
• Shareholders are being asked to vote on four key items.
• The first item is the election of four directors: Waqaas Al-Siddiq, David A. Rosa, Ronald McClurg, and Jainal Bhuiyan.
• The second item is the ratification of SRCO Professional Corporation as the company's independent registered public accounting firm for the year ending March 31, 2025.
• The third item involves approving the issuance of up to $6,600,000 of common stock upon conversion of Series B Convertible Preferred Stock.
• This issuance was conducted via private placement under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(c) of Regulation D, without regard to Nasdaq's 20% Rule.
• The fourth item is to approve the adjournment of the meeting, if necessary, to solicit additional proxies if there are insufficient votes to approve the equity issuance or other proposals.
• The record date for determining shareholders eligible to vote is July 15, 2024.
• The Board of Directors recommends voting FOR all proposals.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, indicating routine corporate governance activities. The need for equity issuance suggests a growth phase or potential funding requirements, which is neither overtly positive nor negative.

Positives

• The Board of Directors is actively recommending shareholders vote in favor of all proposals, indicating confidence in their strategic direction.

Risks

• Failure to secure enough votes for the equity issuance proposal could hinder the company's ability to raise capital through the conversion of preferred stock.
• The need to adjourn the meeting to solicit additional proxies suggests potential difficulty in achieving the required votes for the proposals.

Future Outlook

The document does not contain explicit forward-looking statements beyond the proposals for the annual meeting.

Industry Context

This type of proxy statement is standard for publicly traded companies, outlining key decisions for shareholder voting. The equity issuance proposal suggests a need for capital, which is common in growth-stage companies like Biotricity.

Stakeholder Impact

• Shareholders will directly influence the company's direction through their votes.
• Employees and other stakeholders may be indirectly affected by the outcomes of the proposals, particularly the equity issuance, which could impact the company's financial stability and growth prospects.

Next Steps

• Shareholders need to vote on the proposals before the August 15, 2024 meeting.
• The company will hold the annual meeting and implement the decisions based on shareholder votes.

Key Dates

Keywords

proxy, shareholders, annual meeting, directors, auditor, equity issuance, Biotricity